WO1996040113A3 - Phosphatase inhibitors - Google Patents

Phosphatase inhibitors Download PDF

Info

Publication number
WO1996040113A3
WO1996040113A3 PCT/US1996/009960 US9609960W WO9640113A3 WO 1996040113 A3 WO1996040113 A3 WO 1996040113A3 US 9609960 W US9609960 W US 9609960W WO 9640113 A3 WO9640113 A3 WO 9640113A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
molecules
protein tyrosine
phosphatase activity
tyrosine phosphatase
Prior art date
Application number
PCT/US1996/009960
Other languages
French (fr)
Other versions
WO1996040113A2 (en
Inventor
Gerald Mcmahon
Klaus P Hirth
Peng Cho Tang
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Priority to EP96918441A priority Critical patent/EP0831795A2/en
Priority to AU61104/96A priority patent/AU6110496A/en
Publication of WO1996040113A2 publication Critical patent/WO1996040113A2/en
Publication of WO1996040113A3 publication Critical patent/WO1996040113A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to organic molecules capable of inhibiting protein tyrosine phosphatase activity. The invention further relates to the use of such molecules to modulate or regulate signal transduction by inhibiting protein tyrosine phosphatase activity. Finally, the invention relates to the use of such molecules to treat various disease states including diabetes mellitus.
PCT/US1996/009960 1995-06-07 1996-06-07 Phosphatase inhibitors WO1996040113A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP96918441A EP0831795A2 (en) 1995-06-07 1996-06-07 Phosphatase inhibitors
AU61104/96A AU6110496A (en) 1995-06-07 1996-06-07 Phosphatase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47613795A 1995-06-07 1995-06-07
US476,137 1995-06-07

Publications (2)

Publication Number Publication Date
WO1996040113A2 WO1996040113A2 (en) 1996-12-19
WO1996040113A3 true WO1996040113A3 (en) 1997-01-23

Family

ID=23890656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/009960 WO1996040113A2 (en) 1995-06-07 1996-06-07 Phosphatase inhibitors

Country Status (3)

Country Link
EP (1) EP0831795A2 (en)
AU (1) AU6110496A (en)
WO (1) WO1996040113A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2381397A (en) * 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
ATE554750T1 (en) * 1997-03-05 2012-05-15 Sugen Inc PREPARATIONS CONTAINING HYDROPHOBIC PHARMACEUTICAL ACTIVE INGREDIENTS
US6410585B1 (en) * 1997-08-28 2002-06-25 Scott D. Larsen Inhibitors of protein tyrosine phosphatase
EP1019364B1 (en) 1997-08-28 2004-06-09 Biovitrum Ab Inhibitors of protein tyrosine phosphatase
JP2004500308A (en) * 1998-03-12 2004-01-08 ノボ　ノルディスク　アクティーゼルスカブ Modulator of protein tyrosine phosphatase
US6355786B1 (en) 1998-10-30 2002-03-12 Vanderbilt University Purified and isolated protein zero related (PZR) and therapeutic and screening methods using same
US7064114B2 (en) 1999-03-19 2006-06-20 Parker Hughes Institute Gel-microemulsion formulations
BR0110573A (en) * 2000-05-03 2003-04-01 Hoffmann La Roche Compound, pharmaceutical composition comprising such compound, process for the preparation of a pharmaceutical composition, use of the compound and process for the prophylactic or therapeutic treatment and preparation of the compound
US6498182B2 (en) 2000-09-26 2002-12-24 Biovitrum Ab Compounds
WO2005081954A2 (en) 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
TWI504147B (en) * 2011-06-08 2015-10-11 Linear Techn Inc System to improve the performance of semiconductor based sampling system
WO2013020024A2 (en) * 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3850939A (en) * 1973-02-20 1974-11-26 Parke Davis & Co 5-nitro-2-thiazolylthiopyridine,1-oxides
US3870725A (en) * 1971-03-30 1975-03-11 Lilly Industries Ltd Nitrothiazole derivatives
US5198333A (en) * 1990-03-19 1993-03-30 Agfa-Gevaert, N.V. Photographic materials containing electron accepting agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870725A (en) * 1971-03-30 1975-03-11 Lilly Industries Ltd Nitrothiazole derivatives
US3850939A (en) * 1973-02-20 1974-11-26 Parke Davis & Co 5-nitro-2-thiazolylthiopyridine,1-oxides
US5198333A (en) * 1990-03-19 1993-03-30 Agfa-Gevaert, N.V. Photographic materials containing electron accepting agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S.S. TAYLOR ET AL.: "Structural framework for the protein kinase family.", ANN. REV. CELL BIOL., vol. 8, 1992, pages 429 - 462, XP000609794 *

Also Published As

Publication number Publication date
WO1996040113A2 (en) 1996-12-19
EP0831795A2 (en) 1998-04-01
AU6110496A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
MX9606404A (en) Pharmaceutical compositions and methods for modulating signal transduction.
EP1247803A3 (en) Indolinone compounds suitable for modulation of protein kinases
WO1996040113A3 (en) Phosphatase inhibitors
ATE217865T1 (en) COMPOUNDS FOR INHIBITING PHOSPHODIESRERASE IV
MX9606401A (en) Indolinone compounds for the treatment of disease.
WO1996018738A3 (en) PROBIN TYROSINE KINASE (PYK2) ITS cDNA CLONING AND ITS USES
MX9801093A (en) C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen.
IL143747A0 (en) Substituted aryl or heteroarylamides having retinoid-like biological activity
CA2304657A1 (en) Treatment of conduct disorder
ES2159318T3 (en) INHIBITORS OF PROTEIN QUINASA C.
NL1004070A1 (en) Craps determined by blackjack.
WO1997003188A3 (en) Use of mp52 or mp121 for treating and preventing diseases of the nervous system
WO1994012637A3 (en) Novel human amyloid protein precursor homologue and kunitz-type inhibitors
WO1998024432A3 (en) Use of indolinone compounds as modulators of protein kinases
DK0948604T3 (en) Screening methods for compounds that bind to the PYK2 polypeptide
WO2003073987A3 (en) Compounds that modulate the activity of ptp-1b and tc-ptp
WO1995023217A2 (en) Treatment of diabetes mellitus and insulin receptor signal transduction
WO2002092765A3 (en) Novel telomerase inhibitors and uses therefor
CA2153778A1 (en) Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
CA2212775A1 (en) Thermal decomposition of naphthenic acids
DK0869785T3 (en) 4-Hydroxycoumarin-3-carboxyamides for the treatment of non-insulin-dependent diabetes mellitus
WO2003070965A8 (en) The eaat2 promoter and uses thereof
ATE357914T1 (en) USE OF 4-AMINOPYRIDINE TO TREAT PERIPHERAL NEUROPATHIES
WO1999055859A3 (en) Cd40-interacting and traf-interacting proteins
WO1997030146A3 (en) Cardiotrophin and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE FI GE HU IL IS JP KG KP KR KZ LK LR LS LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE FI GE HU IL IS JP KG KP KR KZ LK LR LS LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996918441

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996918441

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1996918441

Country of ref document: EP